More Harsh Reality from Teva
U.S. healthcare industry leaders from across the spectrum of industry segments continue to downplay the near-term adoption of biosimilars in the...
196 Views
Allergan's Wide Moat Supports Industry-Leading Growth and Profit
Innovative products, strong IP, and an unmatched aesthetics franchise drive Allergan's growth outlook. We anticipate high-single-digit growth for...
241 Views
Our Ultimate Stock-Pickers Top 10 New-Money Purchases
Our early read on the buying and selling activity of our top managers during the second quarter uncovered a few nuggets. New-money purchases were...
160 Views
A 'heads Up' on Changing World Heights
A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest...
165 Views
No Pain, Potential for Lots of Gain for Pfizer, Lilly, and Regeneron
The history of pain drugs that target nerve growth factor has been a roller-coaster ride for drug developers and investors. In 2010, expectations...
171 Views